Profile data is unavailable for this security.
About the company
ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
- Revenue in USD (TTM)0.00
- Net income in USD-8.01m
- Incorporated2007
- Employees21.00
- LocationENDRA Life Sciences Inc3600 Green Ct Ste 350ANN ARBOR 48105-2440United StatesUSA
- Phone+1 (734) 335-0468
- Fax+1 (302) 655-5049
- Websitehttps://www.endrainc.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Burzynski Research Institute Inc | 0.00 | -1.29m | 3.42m | 2.00 | -- | -- | -- | -- | -0.0098 | -0.0098 | 0.00 | -0.0005 | 0.00 | -- | -- | -- | -86,374.50 | -28,790.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -3.80 | -- | -- | -- |
| National Graphite Corp | 0.00 | -1.97m | 3.55m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
| AIM ImmunoTech Inc | 112.00k | -15.75m | 3.57m | 21.00 | -- | -- | -- | 31.87 | -19.82 | -19.82 | 0.1067 | -2.20 | 0.0117 | -- | -- | 5,333.33 | -165.08 | -50.43 | -637.78 | -55.23 | 15.18 | -113.19 | -14,062.50 | -12,238.47 | -- | -- | -- | -- | -15.84 | 3.96 | 40.20 | -- | -45.22 | -- |
| Matinas BioPharma Holdings Inc | 0.00 | -16.87m | 3.78m | 3.00 | -- | 0.539 | -- | -- | -3.30 | -3.30 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -111.43 | -49.82 | -126.56 | -54.00 | -- | -- | -- | -2,545.33 | -- | -- | 0.0025 | -- | -100.00 | -- | -5.71 | -- | -- | -- |
| Nymox Pharmaceutical Corp | -100.00bn | -100.00bn | 3.80m | 3.00 | -- | -- | -- | -- | -- | -- | -- | -0.0717 | -- | -- | -- | -- | -- | -397.74 | -- | -- | -- | -- | -- | -883,740.00 | -- | -- | -- | -- | -- | -- | 49.21 | -- | -- | -- |
| Mosaic Immunoengineering Inc | 0.00 | -671.75k | 3.83m | 2.00 | -- | -- | -- | -- | -0.0928 | -0.0928 | 0.00 | -1.01 | 0.00 | -- | -- | 0.00 | -1,410.50 | -- | -- | -- | -- | -- | -- | -- | -- | -7.37 | -- | -- | -- | -- | 8.56 | -- | -- | -- |
| Revelation Biosciences Inc | 0.00 | -14.08m | 3.86m | 8.00 | -- | 0.1198 | -- | -- | -120.02 | -120.02 | 0.00 | 12.27 | 0.00 | -- | -- | 0.00 | -82.96 | -- | -118.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12,406.06 | -- | -- | -- |
| Silo Pharma Inc | 72.12k | -5.08m | 3.88m | -- | -- | 0.6078 | -- | 53.74 | -0.9262 | -0.9262 | 0.0117 | 0.4788 | 0.0097 | -- | -- | -- | -67.91 | -29.61 | -76.93 | -32.10 | 65.24 | 92.17 | -7,039.37 | -3,630.72 | -- | -- | 0.00 | -- | 0.00 | 12.19 | -20.98 | -- | -- | -- |
| Clearside Biomedical Inc | 3.33m | -26.00m | 3.92m | 32.00 | -- | -- | -- | 1.18 | -5.06 | -5.06 | 0.6461 | -10.31 | 0.1632 | -- | 6.32 | 104,031.30 | -127.43 | -67.79 | -160.28 | -84.94 | 88.07 | -- | -780.90 | -241.58 | -- | -- | 8.48 | -- | -79.77 | -5.20 | -5.75 | -- | 108.16 | -- |
| Indaptus Therapeutics Inc | 0.00 | -16.87m | 3.95m | 7.00 | -- | 0.6274 | -- | -- | -31.67 | -31.67 | 0.00 | 2.81 | 0.00 | -- | -- | 0.00 | -223.71 | -56.08 | -317.86 | -68.84 | -- | -- | -- | -- | -- | -13.74 | 0.00 | -- | -- | -- | 2.60 | -- | -- | -- |
| Galmed Pharmaceuticals Ltd | 0.00 | -8.70m | 4.03m | 3.00 | -- | 0.1757 | -- | -- | -3.60 | -3.60 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -40.91 | -55.02 | -46.34 | -64.19 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.75 | -- | -- | -- |
| ENDRA Life Sciences Inc | 0.00 | -8.01m | 4.09m | 21.00 | -- | 16.12 | -- | -- | -13.35 | -13.35 | 0.00 | 0.2178 | 0.00 | -- | -- | 0.00 | -154.83 | -132.71 | -183.46 | -155.93 | -- | -- | -- | -- | 1.31 | -- | 0.00 | -- | -- | -- | -14.39 | -- | -18.17 | -- |
| Aprea Therapeutics Inc | 488.24k | -13.04m | 4.26m | 8.00 | -- | 0.3339 | -- | 8.73 | -2.14 | -2.14 | 0.08 | 1.95 | 0.0237 | -- | -- | 61,030.00 | -63.27 | -81.97 | -74.72 | -94.17 | -- | -- | -2,670.56 | -11,051.52 | -- | -- | 0.00 | -- | 157.63 | -- | 9.30 | -- | -12.91 | -- |
| Cannabis Bioscience Internatnl Hlgs Inc | 148.34k | -555.16k | 4.65m | 2.00 | -- | -- | -- | 31.35 | -0.00006 | -0.00006 | 0.00001 | -0.0001 | 4.55 | -- | 11.35 | 74,170.00 | -1,702.42 | -652.66 | -- | -- | 73.11 | 87.76 | -374.25 | -177.59 | -- | -4.30 | -- | -- | 21.77 | 0.8662 | 15.74 | -- | -- | -- |
| Genprex Inc | 0.00 | -17.05m | 4.68m | 15.00 | -- | 2.64 | -- | -- | -52.85 | -52.85 | 0.00 | 0.7646 | 0.00 | -- | -- | 0.00 | -448.99 | -100.44 | -1,253.41 | -109.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 30.69 | -- | -- | -- |
| Decoy Therapeutics Inc | 0.00 | -5.00m | 4.72m | 2.00 | -- | 0.1643 | -- | -- | -39.19 | -39.19 | 0.00 | 4.50 | 0.00 | -- | -- | 0.00 | -100.54 | -73.17 | -139.55 | -84.56 | -- | -- | -- | -987.44 | -- | -- | 0.00 | -- | -- | -- | 55.55 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to ENDRA Life Sciences Inc's reporting currency: US Dollar USD
6.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Altium Capital Management LLCas of 31 Dec 2025 | 51.90k | 4.45% |
| DRW Securities LLCas of 30 Sep 2025 | 12.71k | 1.09% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 10.12k | 0.87% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.82k | 0.24% |
| Tower Research Capital LLCas of 30 Sep 2025 | 225.00 | 0.02% |
| The Northwestern Mutual Life Insurance Co. (Invt Port)as of 30 Sep 2025 | 35.00 | 0.00% |
| UBS Securities LLCas of 31 Dec 2025 | 12.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 30 Sep 2025 | 6.00 | 0.00% |
| S.H.N. Financial Investments Ltd.as of 14 Nov 2025 | 0.00 | 0.00% |
| L1 Capital Global, Inc.as of 14 Nov 2025 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 15 Jan 2026Source: FactSet Research Systems Inc.
